William Blair’s Kevin Eisele, managing director on the firm’s equity capital markets team, connected recently with the Wall Street Journal to discuss the current trends surrounding venture capital’s appetite for investments in biotech companies.
Eisele points out in the article that while there is continued interest from VCs in biotech companies, noting that the producers of novel and innovative products like biotech products are seemingly always attractive, the numbers since the COVID-19 era peak are still in decline.